VR Logo

Enanta Pharmaceuticals Inc. (ENTA) download report


Healthcare | Biotechnology & Pharma Research

Enanta Pharmaceuticals Inc. (ENTA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.

IPO Date: 21-Mar-2013

Pres, CEO & Director: Dr. Jay R. Luly

Sr. VP of Fin. & Admin. and CFO: Mr. Paul J. Mellett Jr.

Listing: NASDAQ: ENTA

Country: United States

Headquarters: Watertown, MA

Website: https://www.enanta.com

Key Facts

Market cap: $922.75 Mln

Revenue (TTM): $91.56 Mln

Earnings (TTM): $-112.33 Mln

Cash: $280.33 Mln

Total Debt: $18.13 Mln

Insider's Holding: 6.09%

Liquidity: Low

52 Week range: $37.59 - 102.00

Shares outstanding: 20,712,700

10 Years Aggregate:

  • CFO: $256.32 Mln
  • EBITDA: $257.17 Mln
  • Net Profit: $187.01 Mln

Stock Performance

Time Period Enanta Pharmaceuticals (ENTA) S&P BSE Sensex* S&P Small-Cap 600*
YTD-37.27-8.99-19.22
1 month18.85-3.40-9.34
3 months-30.93-8.50-14.58
1 Year4.290.89-17.64
3 Years-17.7710.415.91
5 Years4.8311.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year Enanta Pharmaceuticals (ENTA) S&P Small-Cap 600 S&P BSE Sensex
202177.6225.2721.99
2020-31.859.5715.75
2019-12.7820.8614.38
201820.58-9.705.87
201775.1611.7327.91
20161.4524.741.95
2015-35.06-3.36-5.03